JPRN-UMIN000011005已完成未知
Ezetimibe 10 mg + rosuvastatin 2.5 mg versus rosuvastatin 5 mg for hypercholesterolemia in patients with type 2 diabetes - Ezetimibe 10 mg + rosuvastatin 2.5 mg versus rosuvastatin 5 mg for hypercholesterolemia in patients with type 2 diabetes
First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health0 个研究点目标入组 80 人开始时间: 2013年6月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with a history of familial hypercholesterolemia, patients who have developed stroke or ischemic heart disease within the past six months, patients with liver failure (ALT and/or AST >80 IU/L) or kidney failure (serum creatinine >1.3 mg/dL), patients using insulin, patients who are pregnant or could possibly become pregnant, and patients who are breast feeding are excluded from the study.
研究者
相似试验
已完成
不适用
comparison of rosuvastatin alone versus ezetimib plus standard statin on lipid-lowering effects in patients with dyslipidemiadyslipidemiaJPRN-UMIN000002802Department of Medicine II, Hokkaido University Graduate School of Medicine100
招募中
不适用
The effect of usual dose rosuvastatin plus ezetimibe versus high-dose rosuvastatin on coronary atherosclerotic plaqueDiseases of the circulatory systemKCT0003092Samsung Medical Center280
已完成
4 期
Efficacy of Ezetimibe vs Rosuvastatin In Impaired Glucose Tolerance Hypercholesterolemia to TreatHypercholesterolemiaJPRN-UMIN000008049Jikei University School of Medicine,Kashiwa Hospital150
进行中（未招募）
Unknown
Switch to rosuvastatin plus ezetimibe treatment from statin monotherapy for Target LDL-C goal achievement in patients with ischemic stroke, TIA or cerebral atherosclerosis: A multi-center, open-label, single arm phase IV trial (S-ROSETTA-Stroke)Endocrine, nutritional and metabolic diseasesKCT0008455Inje University Ilsan Paik Hospital410
已完成
4 期
Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DMAtherosclerotic Cardiovascular DiseaseType 2 Diabetes MellitusNCT03597412Yuhan Corporation236